Clinical trial
Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With…
NCT00017407 · Ionis Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00017407 |
|---|---|
| Title | Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer |
| Official title | A Prospective, Randomized, Open-label, Phase III Trial of Chemotherapy With Carboplatin And Paclitaxel, Versus Carboplatin And Paclitaxel In Combination With ISIS-3521, An Antisense Inhibitor Of Protein Kinase C Alpha In Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer |
| Lead sponsor | Ionis Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | ISIS 3521, carboplatin, paclitaxel |
| Start date | Oct 13, 2000 |
| Primary completion | Sep 9, 2002 |
| Completion | Sep 9, 2002 |
| First posted | Feb 4, 2004 |
| Last update posted | Dec 5, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: